S. aureus
Phase 1Small molecule
S. aureus is one of 29 small molecule programs targeting Skin Infection. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Skin Infection
#DrugCompanyPhaseTrials
1Keflex
Eli LillyApproved
Omnicef
AbbVieApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Lotrimin
BayerApproved
Cubicin
BBaxter Healthcare Corporation
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Betadine
BBecton, Dickinson and Company
Approved
Teflaro
AbbViePhase 3
Levaquin
WWim Janssens
Phase 3
Ampicillin-Sulbactam
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Skin Infection1 trial
Human Immunity Against Staphylococcus Aureus Skin Infection
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02262819·49 enrolled
TED1 trial
Targeted Investigation of Microbiome Elimination
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05177328·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S. aureus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details